Loading patent…
AssigneesMahidol University, Riken, Department of Medical Sciences
InventorsSomnuek Sungkanuparph, Sasisopin Kiertiburanakul, Thanyachai Sura, Wasun Chantratita, Soranun Chantarangsu, Angkana Charoenyingwattana, Surakameth Mahasirimongkol, Michiaki Kubo, Taisei Mushiroda, Yusuke Nakamura
Estimating the term…
The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.
A method of assessing the risk of a patient for developing a cutanoeus adverse reaction to non-nucleoside reverse transcriptase inhibitor such as nevirapine by using CD4 count, drug allergy history and/or HLA-B*3505 allele wherein the presence of HLA-B*3505 allele is indicative of a risk for a cutaneous adverse drug reaction to nevirapine.
A method of assessing the risk of a patient for developing a cutanoeus adverse reaction to non-nucleoside reverse transcriptase inhibitor such as nevirapine by using CD4 count, drug allergy history and/or polymorphisms in CCHCR1 gene wherein the presence of polymorphisms in CCHCR1 gene are indicative of a risk for a cutaneous adverse drug reaction to nevirapine.
(canceled)
(canceled)
A method of assessing the risk of a patient for developing a cutanoeus adverse reaction to non-nucleoside reverse transcriptase inhibitor such as nevirapine by using CD4 count, drug allergy history and/or polymorphisms in POLR3G gene wherein the presence of polymorphisms in POLR3G gene are indicative of a risk for a cutaneous adverse drug reaction to nevirapine.
Dependencies are inferred from the claim text.